Symbols / FLNA Stock $1.56 -3.11% Filana Therapeutics, Inc.
FLNA (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-10-06 | init | LUCID CAPITAL MARKETS | — → Buy | $8 |
- Cassava Sciences (FLNA) Financials 2026 - Income Statement and Balance Sheet $FLNA - MarketBeat ue, 28 Apr 2026 03
- symbol__ Stock Quote Price and Forecast - CNN Fri, 13 Mar 2026 02
- FLNA Stock Price, News & Analysis - Stock Titan ue, 10 Mar 2026 12
- FLNA Stock Price and Chart — NASDAQ:FLNA - TradingView Wed, 11 Mar 2026 18
- FLNA Filana Therapeutics reports narrower Q3 2025 loss than expected, shares rise 1.45 percent in today’s session. - Meet Estimates - Cổng thông tin điện tử tỉnh Lào Cai Wed, 22 Apr 2026 20
- FLNA Price Today: Filana Therapeutics, Inc. Stock Price, Quote & Chart - MEXC Fri, 13 Mar 2026 10
- FLNA Filana Therapeutics posts narrower than expected Q3 2025 loss, shares edge higher in today’s trading. - Market Hype Signals - Cổng thông tin điện tử Tỉnh Sơn La Wed, 22 Apr 2026 17
- Cassava Sciences Announces Name Change to Filana Therapeutics, Inc. - Yahoo Finance ue, 10 Mar 2026 07
- MSN Money - MSN Wed, 15 Apr 2026 07
- Cassava Sciences (FLNA) Institutional Ownership 2026 $FLNA - MarketBeat Fri, 24 Apr 2026 07
- Filana leaves Cassava roots behind amid branch into epilepsy - Fierce Pharma ue, 10 Mar 2026 07
- FLNA|Cassava Sciences Ord Shs|Price:1.625|Chg%:-0.03 - TradingKey Mon, 13 Apr 2026 12
- Filamin A-focused Filana Therapeutics replaces Cassava Sciences - Stock Titan ue, 10 Mar 2026 07
- FLNA Forecast — Price Target — Prediction for 2027 - TradingView Wed, 11 Mar 2026 19
- What is the valuation of Filana Therapeutics (FLNA) Stock | Price at $1.70, Up 1.50% - Viral Momentum Stocks - Cổng thông tin điện tử tỉnh Lào Cai Wed, 08 Apr 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
96.13
-32.44%
|
142.28
+32.56%
|
107.33
+31.73%
|
81.48
|
| Research And Development |
|
26.59
-61.82%
|
69.64
-22.13%
|
89.42
+31.44%
|
68.03
|
| Selling General And Administration |
|
68.80
-4.19%
|
71.81
+334.31%
|
16.53
+37.92%
|
11.99
|
| General And Administrative Expense |
|
68.80
-4.19%
|
71.81
+334.31%
|
16.53
+37.92%
|
11.99
|
| Other Gand A |
|
68.80
-4.19%
|
71.81
+334.31%
|
16.53
+37.92%
|
11.99
|
| Other Operating Expenses |
|
0.74
-11.64%
|
0.83
-39.46%
|
1.38
-5.88%
|
1.46
|
| Total Expenses |
|
96.13
-32.44%
|
142.28
+32.56%
|
107.33
+31.73%
|
81.48
|
| Operating Income |
|
-96.13
+32.44%
|
-142.28
-32.56%
|
-107.33
-31.73%
|
-81.48
|
| Total Operating Income As Reported |
|
-95.39
+32.56%
|
-141.45
-33.49%
|
-105.96
-32.41%
|
-80.02
|
| EBITDA |
|
-95.19
+32.56%
|
-141.15
-33.41%
|
-105.80
-31.96%
|
-80.18
|
| Normalized EBITDA |
|
-95.19
+61.82%
|
-249.33
-135.65%
|
-105.80
-31.96%
|
-80.18
|
| Reconciled Depreciation |
|
0.94
-17.31%
|
1.13
-26.01%
|
1.53
+17.60%
|
1.30
|
| EBIT |
|
-96.13
+32.44%
|
-142.28
-32.56%
|
-107.33
-31.73%
|
-81.48
|
| Total Unusual Items |
|
—
|
108.18
|
—
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
—
|
108.18
|
—
|
0.00
|
| Special Income Charges |
|
—
|
—
|
—
|
0.00
|
| Net Income |
|
-90.97
-273.73%
|
-24.34
+74.96%
|
-97.22
-27.50%
|
-76.25
|
| Pretax Income |
|
-90.97
-273.73%
|
-24.34
+74.96%
|
-97.22
-27.50%
|
-76.25
|
| Net Non Operating Interest Income Expense |
|
4.62
-45.71%
|
8.51
+8.64%
|
7.83
+182.07%
|
2.78
|
| Net Interest Income |
|
4.62
-45.71%
|
8.51
+8.64%
|
7.83
+182.07%
|
2.78
|
| Interest Income Non Operating |
|
4.62
-45.71%
|
8.51
+8.64%
|
7.83
+182.07%
|
2.78
|
| Interest Income |
|
4.62
-45.71%
|
8.51
+8.64%
|
7.83
+182.07%
|
2.78
|
| Other Income Expense |
|
0.53
-99.51%
|
109.43
+4693.12%
|
2.28
-7.16%
|
2.46
|
| Other Non Operating Income Expenses |
|
0.53
-57.15%
|
1.24
-45.51%
|
2.28
-7.16%
|
2.46
|
| Gain On Sale Of Security |
|
—
|
108.18
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-90.97
-273.73%
|
-24.34
+74.96%
|
-97.22
-27.50%
|
-76.25
|
| Net Income From Continuing Operation Net Minority Interest |
|
-90.97
-273.73%
|
-24.34
+74.96%
|
-97.22
-27.50%
|
-76.25
|
| Net Income From Continuing And Discontinued Operation |
|
-90.97
-273.73%
|
-24.34
+74.96%
|
-97.22
-27.50%
|
-76.25
|
| Net Income Continuous Operations |
|
-90.97
-273.73%
|
-24.34
+74.96%
|
-97.22
-27.50%
|
-76.25
|
| Normalized Income |
|
-90.97
+31.35%
|
-132.53
-36.32%
|
-97.22
-27.50%
|
-76.25
|
| Net Income Common Stockholders |
|
-90.97
-273.73%
|
-24.34
+74.96%
|
-97.22
-27.50%
|
-76.25
|
| Diluted EPS |
|
-1.88
-28.77%
|
-1.46
+37.07%
|
-2.32
-22.11%
|
-1.90
|
| Basic EPS |
|
-1.88
-254.72%
|
-0.53
+77.16%
|
-2.32
-22.11%
|
-1.90
|
| Basic Average Shares |
|
48.30
+4.25%
|
46.33
+10.49%
|
41.93
+4.30%
|
40.20
|
| Diluted Average Shares |
|
48.30
+3.63%
|
46.60
+11.14%
|
41.93
+4.30%
|
40.20
|
| Diluted NI Availto Com Stockholders |
|
-90.97
-33.52%
|
-68.14
+29.91%
|
-97.22
-27.50%
|
-76.25
|
| Average Dilution Earnings |
|
0.00
+100.00%
|
-43.79
|
0.00
|
0.00
|
| Gain On Sale Of PPE |
|
—
|
—
|
—
|
0.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
118.36
-24.87%
|
157.53
+3.87%
|
151.66
-35.42%
|
234.83
|
| Current Assets |
|
97.71
-28.44%
|
136.53
+5.32%
|
129.63
-38.63%
|
211.23
|
| Cash Cash Equivalents And Short Term Investments |
|
95.50
-25.72%
|
128.57
+6.14%
|
121.14
-39.74%
|
201.01
|
| Cash And Cash Equivalents |
|
95.50
-25.72%
|
128.57
+6.14%
|
121.14
-39.74%
|
201.01
|
| Receivables |
|
0.12
-87.33%
|
0.95
-1.56%
|
0.96
|
0.00
|
| Accrued Interest Receivable |
|
0.12
-87.33%
|
0.95
-1.56%
|
0.96
|
0.00
|
| Prepaid Assets |
|
2.02
-70.99%
|
6.97
-3.79%
|
7.25
-27.89%
|
10.05
|
| Other Current Assets |
|
0.06
+68.42%
|
0.04
-86.76%
|
0.29
+79.38%
|
0.16
|
| Total Non Current Assets |
|
20.65
-1.69%
|
21.00
-4.67%
|
22.03
-6.68%
|
23.61
|
| Net PPE |
|
20.65
-1.69%
|
21.00
-3.90%
|
21.85
-4.92%
|
22.99
|
| Gross PPE |
|
24.79
+2.26%
|
24.24
+0.41%
|
24.14
-0.20%
|
24.19
|
| Accumulated Depreciation |
|
-4.14
-27.90%
|
-3.24
-41.68%
|
-2.28
-90.33%
|
-1.20
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Land And Improvements |
|
3.73
+0.00%
|
3.73
+0.00%
|
3.73
+0.00%
|
3.73
|
| Buildings And Improvements |
|
15.98
+0.00%
|
15.98
+0.00%
|
15.98
-0.76%
|
16.10
|
| Machinery Furniture Equipment |
|
0.89
+1.83%
|
0.88
+0.81%
|
0.87
+2.00%
|
0.85
|
| Construction In Progress |
|
0.03
-54.55%
|
0.06
|
0.00
-100.00%
|
0.01
|
| Other Properties |
|
0.69
+29.38%
|
0.53
+7.49%
|
0.49
+5.11%
|
0.47
|
| Leases |
|
3.47
+13.26%
|
3.06
+0.00%
|
3.06
+1.53%
|
3.02
|
| Goodwill And Other Intangible Assets |
|
—
|
0.04
-78.98%
|
0.18
-71.70%
|
0.62
|
| Other Intangible Assets |
|
—
|
0.04
-78.98%
|
0.18
-71.70%
|
0.62
|
| Other Non Current Assets |
|
—
|
—
|
—
|
—
|
| Total Liabilities Net Minority Interest |
|
43.95
+271.56%
|
11.83
-16.67%
|
14.20
+94.59%
|
7.29
|
| Current Liabilities |
|
43.83
+273.06%
|
11.75
-17.22%
|
14.20
+100.98%
|
7.06
|
| Payables And Accrued Expenses |
|
42.01
+316.20%
|
10.09
-25.83%
|
13.61
+116.13%
|
6.30
|
| Payables |
|
41.65
+444.12%
|
7.65
-27.61%
|
10.57
+163.21%
|
4.02
|
| Accounts Payable |
|
41.65
+444.12%
|
7.65
-27.61%
|
10.57
+163.21%
|
4.02
|
| Current Accrued Expenses |
|
0.36
-85.08%
|
2.44
-19.66%
|
3.04
+33.20%
|
2.28
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
1.62
+19.75%
|
1.36
+578.50%
|
0.20
+17.65%
|
0.17
|
| Current Debt And Capital Lease Obligation |
|
—
|
—
|
—
|
0.10
|
| Current Capital Lease Obligation |
|
—
|
—
|
0.00
-100.00%
|
0.10
|
| Other Current Liabilities |
|
0.20
-33.78%
|
0.30
-22.34%
|
0.39
-21.75%
|
0.49
|
| Total Non Current Liabilities Net Minority Interest |
|
0.12
+49.37%
|
0.08
|
0.00
-100.00%
|
0.23
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
—
|
0.00
-100.00%
|
0.04
|
| Long Term Capital Lease Obligation |
|
—
|
—
|
0.00
-100.00%
|
0.04
|
| Other Non Current Liabilities |
|
0.12
+49.37%
|
0.08
|
—
|
0.20
|
| Stockholders Equity |
|
74.40
-48.94%
|
145.70
+5.99%
|
137.47
-39.58%
|
227.54
|
| Common Stock Equity |
|
74.40
-48.94%
|
145.70
+5.99%
|
137.47
-39.58%
|
227.54
|
| Capital Stock |
|
0.05
+0.00%
|
0.05
+14.29%
|
0.04
+0.00%
|
0.04
|
| Common Stock |
|
0.05
+0.00%
|
0.05
+14.29%
|
0.04
+0.00%
|
0.04
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
48.31
+0.22%
|
48.20
+14.13%
|
42.24
+1.20%
|
41.74
|
| Ordinary Shares Number |
|
48.31
+0.22%
|
48.20
+14.13%
|
42.24
+1.20%
|
41.74
|
| Additional Paid In Capital |
|
570.44
+3.57%
|
550.77
+6.29%
|
518.20
+1.40%
|
511.05
|
| Retained Earnings |
|
-496.08
-22.46%
|
-405.11
-6.39%
|
-380.77
-34.29%
|
-283.55
|
| Total Equity Gross Minority Interest |
|
74.40
-48.94%
|
145.70
+5.99%
|
137.47
-39.58%
|
227.54
|
| Total Capitalization |
|
74.40
-48.94%
|
145.70
+5.99%
|
137.47
-39.58%
|
227.54
|
| Working Capital |
|
53.88
-56.82%
|
124.78
+8.09%
|
115.44
-43.46%
|
204.16
|
| Invested Capital |
|
74.40
-48.94%
|
145.70
+5.99%
|
137.47
-39.58%
|
227.54
|
| Total Debt |
|
—
|
—
|
0.00
-100.00%
|
0.14
|
| Capital Lease Obligations |
|
—
|
—
|
0.00
-100.00%
|
0.14
|
| Net Tangible Assets |
|
74.40
-48.94%
|
145.70
+6.13%
|
137.29
-39.50%
|
226.92
|
| Tangible Book Value |
|
74.40
-48.94%
|
145.70
+6.13%
|
137.29
-39.50%
|
226.92
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-32.25
+72.42%
|
-116.93
-42.55%
|
-82.03
-5.82%
|
-77.51
|
| Cash Flow From Continuing Operating Activities |
|
-32.25
+72.42%
|
-116.93
-42.55%
|
-82.03
-5.82%
|
-77.51
|
| Net Income From Continuing Operations |
|
-90.97
-273.73%
|
-24.34
+74.96%
|
-97.22
-27.50%
|
-76.25
|
| Depreciation Amortization Depletion |
|
0.94
-17.31%
|
1.13
-26.01%
|
1.53
+17.60%
|
1.30
|
| Depreciation |
|
0.90
-5.15%
|
0.95
-12.18%
|
1.08
+34.83%
|
0.80
|
| Amortization Cash Flow |
|
0.03
-81.67%
|
0.18
-59.64%
|
0.45
-10.26%
|
0.50
|
| Depreciation And Amortization |
|
0.94
-17.31%
|
1.13
-26.01%
|
1.53
+17.60%
|
1.30
|
| Amortization Of Intangibles |
|
0.03
-81.67%
|
0.18
-59.64%
|
0.45
-10.26%
|
0.50
|
| Stock Based Compensation |
|
19.58
+20.20%
|
16.29
+255.23%
|
4.59
+121.97%
|
2.07
|
| Operating Gains Losses |
|
—
|
-108.18
|
—
|
—
|
| Gain Loss On Investment Securities |
|
—
|
-108.18
|
—
|
—
|
| Gain Loss On Sale Of PPE |
|
—
|
—
|
—
|
0.00
|
| Change In Working Capital |
|
38.20
+2191.02%
|
-1.83
-120.13%
|
9.08
+295.81%
|
-4.63
|
| Change In Prepaid Assets |
|
6.08
+1028.01%
|
0.54
-68.55%
|
1.71
+44.15%
|
1.19
|
| Change In Payables And Accrued Expense |
|
31.92
+1007.76%
|
-3.52
-145.94%
|
7.65
+292.67%
|
-3.97
|
| Change In Accrued Expense |
|
-2.08
-247.74%
|
-0.60
-178.86%
|
0.76
+244.74%
|
-0.52
|
| Change In Payable |
|
33.99
+1264.54%
|
-2.92
-142.33%
|
6.90
+299.94%
|
-3.45
|
| Change In Account Payable |
|
33.99
+1264.54%
|
-2.92
-142.33%
|
6.90
+299.94%
|
-3.45
|
| Change In Other Working Capital |
|
0.27
-76.84%
|
1.16
+8800.00%
|
0.01
+100.76%
|
-1.72
|
| Change In Other Current Liabilities |
|
-0.06
-785.71%
|
-0.01
+97.70%
|
-0.30
-123.53%
|
-0.14
|
| Investing Cash Flow |
|
-0.58
-464.08%
|
-0.10
+75.12%
|
-0.41
+84.73%
|
-2.71
|
| Cash Flow From Continuing Investing Activities |
|
-0.58
-464.08%
|
-0.10
+75.12%
|
-0.41
+84.73%
|
-2.71
|
| Net PPE Purchase And Sale |
|
-0.58
-464.08%
|
-0.10
+75.12%
|
-0.41
+84.73%
|
-2.71
|
| Purchase Of PPE |
|
-0.58
-464.08%
|
-0.10
+75.12%
|
-0.41
+84.73%
|
-2.71
|
| Sale Of PPE |
|
—
|
—
|
—
|
0.00
|
| Capital Expenditure |
|
-0.58
-464.08%
|
-0.10
+75.12%
|
-0.41
+84.73%
|
-2.71
|
| Financing Cash Flow |
|
-0.24
-100.19%
|
124.47
+4762.11%
|
2.56
-94.64%
|
47.80
|
| Cash Flow From Continuing Financing Activities |
|
-0.24
-100.19%
|
124.47
+4762.11%
|
2.56
-94.64%
|
47.80
|
| Net Common Stock Issuance |
|
—
|
0.00
|
0.00
-100.00%
|
47.33
|
| Proceeds From Stock Option Exercised |
|
0.09
-99.93%
|
124.47
+4762.11%
|
2.56
+438.95%
|
0.47
|
| Net Other Financing Charges |
|
-0.33
|
—
|
—
|
—
|
| Changes In Cash |
|
-33.07
-544.64%
|
7.44
+109.31%
|
-79.88
-146.37%
|
-32.42
|
| Beginning Cash Position |
|
128.57
+6.14%
|
121.14
-39.74%
|
201.01
-13.89%
|
233.44
|
| End Cash Position |
|
95.50
-25.72%
|
128.57
+6.14%
|
121.14
-39.74%
|
201.01
|
| Free Cash Flow |
|
-32.83
+71.95%
|
-117.03
-41.96%
|
-82.44
-2.76%
|
-80.23
|
| Common Stock Issuance |
|
—
|
0.00
|
0.00
-100.00%
|
47.33
|
| Issuance Of Capital Stock |
|
—
|
0.00
|
0.00
-100.00%
|
47.33
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-K2026-03-12 View
- 8-K2026-03-12 View
- 8-K2026-03-10 View
- 8-K2026-02-19 View
- 8-K2025-12-23 View
- 8-K2025-12-18 View
- 8-K2025-12-17 View
- 8-K2025-12-03 View
- 42025-11-25 View
- 42025-11-24 View
- 42025-11-20 View
- 10-Q2025-11-12 View
- 8-K2025-11-12 View
- 8-K2025-10-24 View
- 42025-10-22 View
- 8-K2025-10-22 View
- 42025-10-02 View
- 42025-09-23 View
- 42025-09-22 View
- 8-K2025-09-08 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|